Clinical trials: Melancholia
Depression, Melancholia
Antidepressant Treatment of Melancholia in Late Life
The purpose of this study is to compare the safety and effectiveness of a select serotonin re-uptake inhibitor (SSRI, sertraline) and a tricyclic antidepressant (TCA, nortriptyline) in outpatients over the age of 60 who have…
- Trial name
- NCT00000378
- Testing
- Sertraline, Nortriptyline
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- New York State Psychiatric Institute
Depressive Disorder, Major
Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder
The purpose of this study is to assess the efficacy and safety of multiple doses of vortioxetine, once daily (QD), in participants with major depressive disorder.
- Trial name
- NCT01255787
- Testing
- Vortioxetine
- Where
- 70 sites in Croatia, Finland and 14 more
- Volunteers
- 600 people
- Sponsor
- Takeda
Depressive Disorder, Major
Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy of vortioxetine, once daily (QD), compared with placebo in adults with major depressive disorder.
- Trial name
- NCT01163266
- Testing
- Vortioxetine
- Where
- 39 sites in United States
- Volunteers
- 462 people
- Sponsor
- Takeda
Major Depressive Disorder
Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to determine the effectiveness and safety of vortioxetine, once daily (QD), in patients with Major Depressive Disorder.
- Trial name
- NCT00735709
- Testing
- Vortioxetine
- Where
- 48 sites in Australia, Czechia and 13 more
- Volunteers
- 560 people
- Sponsor
- Takeda
Major Depressive Disorder
Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to determine the long-term efficacy and safety of vortioxetine, once daily (QD), in adults with major depressive disorder.
- Trial name
- NCT00707980
- Testing
- Vortioxetine
- Where
- 92 sites in United States, Australia and 15 more
- Volunteers
- 836 people
- Sponsor
- Takeda
Depressive Disorder, Major
Melancholic Depression and Insomnia as Predictors of Response to Quetiapine in Patients With Major Depression
In essence the researchers are hoping to test two separate hypotheses (described below in the form of research questions). Therefore, the proposed analysis has been outlined according to each hypothesis.
- Trial name
- NCT03207438
- Testing
- Quetiapine 50 MG Extended Release Oral Tablet, Quetiapine Fumarate XR 150-300 mg
- Volunteers
- 1,790 people
- Sponsor
- University of Saskatchewan
Major Depressive Disorder, Healthy Controls
Effects of Treatment on Decision-making in Major Depression
In this trial, fifty participants with current major depressive disorder who are not receiving an antidepressant medication and fifty healthy controls will complete questionnaires and computerized tasks to assess their…
- Trial name
- NCT01916824
- Testing
- Any FDA Approved Antidepressant
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Emory University
Depression, Bipolar Disorder
Melancholic Symptoms in Bipolar Depression and Responsiveness to Lamotrigine
The purpose of this study is to determine if patients with melancholic bipolar II depression are more responsive to lamotrigine than patients with non-melancholic bipolar II depression.
- Conditions
- Depression, Bipolar Disorder, Bipolar Depression, Melancholia
- Trial name
- NCT02989727
- Testing
- Lamotrigine
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- University of Saskatchewan
Depressive Disorder, Major
Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety and tolerability of vortioxetine, once daily (QD), compared with placebo in adults with major depressive disorder.
- Trial name
- NCT01153009
- Testing
- Vortioxetine, Duloxetine
- Where
- 56 sites in United States
- Volunteers
- 614 people
- Sponsor
- Takeda
Depressive Disorder, Major
Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study
The purpose of this study is to determine the long-term safety and tolerability of vortioxetine, once daily (QD), in participants with major depressive disorder.
- Trial name
- NCT01152996
- Testing
- Vortioxetine
- Volunteers
- 1,075 people
- Sponsor
- Takeda